Urogenital effects of selective estrogen receptor modulators: a systematic review

References

• Sartori MGF, Baracat EC, Gird° MJBC, Gon-çalves WJ, Sartori JP, Rodrigues de Lima G. Menopausal genuine stress urinary incontinence treated with conjugated estrogen plus progesto-gens. Int J Gynecol Obstet 1995;49:165–9
   Google Scholar
• Rekers H, Drogendijk AC, Valkenburg HA, Riphagen F. The menopause, urinary inconti-nence and other symptoms of the genito-urinary tract. Maturitas 1992;15:101–11
   PubMed Web of Science ®Google Scholar
• Casper RF, McPherson R, Ste-Marie LG. The Canadian Consensus Conference on Menopause and Osteoporosis. J Soc Obstet Gynaecol Can 1998;20:1243–72
   Google Scholar
• Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103:254–60
   PubMed Web of Science ®Google Scholar
• Purdie DW, Albertazzi P. Selective oestrogen receptor modulators (SERMs) in postmenopau-sal women's health. Reprod Med Rev 2000;8: 215–28
   Google Scholar
• Friedrich M, Mink D, Villena-Heinsen C, Woll-Hermann A, Schmidt W. Tamoxifen and pro-liferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol 1998;80:221–5
   Google Scholar
• Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003;189: 81–8
   PubMed Web of Science ®Google Scholar
• Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast can-cer: a follow-up study. J Natl Cancer Inst 2002;94:39-49. Erratum in J Natl Cancer Inst 2002;94: 463
   Google Scholar
• Goldstein SR. Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer 2000; 36(Suppl 4):54–6
   Google Scholar
• Silfen SL, Ciaccia AV, Bryant HU. Selective estrogen receptor modulators: tissue specificity and differential uterine effects. Climacteric 1999;2:268–83
   Google Scholar
• Hendrix SL, McNeeley G. Effects of selective receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci 2001;949:243–50
   PubMed Web of Science ®Google Scholar
• Ciaccia A, Goldstein S, Johnson S, Watts, Draper M, Plouffe L Jr. Incidence and severity of urinary incontinence in postmenopausal women participating in a placebo-controlled trial of raloxifene and estrogen. J Am Geriatr Soc 2002;50(4 Suppl):5134
   Google Scholar
• Goldstein SR, Neven P, Zhour U, Taylor YU, Ciaccia AV, Plouffe Jr L. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001;98:91–6
   Google Scholar
• Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558–65
   Google Scholar
• Waetjen LE, Brown JS, Modelska K, Blackwell T, Vittinghoff E, Cummings SR; MORE Study Group. Effect of raloxifene on urinary incon-tinence: a randomized controlled trial. Obstet Gynecol 2004;103:261–6
   Google Scholar
• Tomas E, Kauppila A, Blanco G, Apaja-Sarkki-nen M, Laatikaine T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59:261–6
   Google Scholar
• Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antiestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2000; 84:897–902
   Web of Science ®Google Scholar
• Gams R. Phase III trials of toremifene vs tamoxifen. Oncology (Huntingt) 1997;11(5 Suppl 4):23–8
   Google Scholar
• SmithKline Beecham drops idoxifene for osteo-porosis. Script 1999;2431:21, PJB Publications Ltd
   Google Scholar
• Novo Nordisk drops Levormeloxifene. Script 1998;23:18,PJB Publications Ltd
   Google Scholar
• Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen recep-tor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521–7
   PubMed Web of Science ®Google Scholar
• Warming L, Christoffersen C, Riis BJ, Stakkes-tad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44: 189–99
   Google Scholar
• Burning PF. Droloxifene, a new anti-estrogen in postmenopausal advanced breast cancer: preli-minary results of a double blind dose finding phase II trial. Eur J Cancer 1992;28A:1404–7
   PubMed Web of Science ®Google Scholar
• Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospe-mifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002;43:207–14
   PubMed Web of Science ®Google Scholar
• Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala 0. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10: 433–9
   Google Scholar
• Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 2003;90:540–6
   Web of Science ®Google Scholar
• Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol 2001;97:116–20
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Drug therapy: selective estrogen receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618–29
   PubMed Web of Science ®Google Scholar
• Brincat M, Kabalan S, Studd JWW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness and bone mass in the postmenopausal woman. Obstet Gynecol 1987;70:840–5
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Pons F, Gratacos E, Fortuny A, Vanrell JA, Gonzales-Merlo J. Relationship between collagen and bone change during aging. Maturitas 1994;18:199–204
   Google Scholar
• Bergman A, Elia G, Cheung D, Perelman N, Nimni ME. Biochemical composition of collagen in continent and stress urinary incontinent women. Gynecol Obstet Invest 1994;37:48–51
   Google Scholar
• Falconer C, Ekman G, Malmstrom A, Ulmster U. Decrease collagen synthesis in stress incon-tinent women. Obstet Gynecol 1994;84:583–6
   PubMed Web of Science ®Google Scholar
• Versi, Cardozo LD, Brincat M, et al. Correlation of urethral physiology and skin collagen in post-menopausal women. Br J Obstet Gynaecol 1988;95:147–52
   PubMedGoogle Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721–5
   PubMed Web of Science ®Google Scholar